Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Glucagon-like peptide-1, glucose homeostasis and diabetes

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Sphingosine-1-Phosphate Signaling in Inflammatory Bowel Disease

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. Exercise-Dependent Regulation of NK Cells in Cancer Protection

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  3. Endothelial Glycocalyx: Shedding Light on Malaria Pathogenesis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Inhibitors of apoptosis (IAPs) regulate intestinal immunity and inflammatory bowel disease (IBD) inflammation

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer
Incretins, enhancers of insulin secretion, are essential for glucose tolerance, and a reduction in their function might contribute to poor beta-cell function in patients with type-2 diabetes mellitus. However, at supraphysiological doses, the incretin glucagon-like peptide-1 (GLP-1) protects pancreatic beta cells, and inhibits glucagon secretion, gastric emptying and food intake, leading to weight loss. GLP-1 mimetics, which are stable-peptide-based activators of the GLP-1 receptor, and incretin enhancers, which inhibit the incretin-degrading enzyme dipeptidyl peptidase-4, have emerged as therapies for type-2 diabetes and have recently reached the market. The pathophysiological basis the clinical use of these therapeutics is reviewed here.
OriginalsprogEngelsk
TidsskriftTrends in Molecular Medicine
Vol/bind14
Udgave nummer4
Sider (fra-til)161-8
Antal sider8
ISSN1471-4914
DOI
StatusUdgivet - 1 apr. 2008

ID: 32267430